Yuekang Pharmaceutical (688658.SH) subsidiary YKYY013 injection obtains clinical trial approval.

Wisdom Financial APP News, Yuekang Pharmaceutical (688658.SH) announced that its subsidiaries Beijing Yuekang Science and Technology Pharmaceutical Technology Co., Ltd. (referred to as "Yuekang Science and Technology") and Hangzhou Tianlong Pharmaceutical Co., Ltd. (referred to as "Hangzhou Tianlong") recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for YKYY013 injection for the treatment of chronic hepatitis B virus infection. The company will conduct Phase I clinical trials of this product.